A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

This study has been completed.

Study NCT00660829 Information provided by Meda Pharmaceuticals

First Received on April 14, 2008. Last Updated on February 19, 2010 History of Changes

Results First Received: September 30, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Seasonal Allergic Rhinitis
Interventions:	Drug: Placebo Drug: 0.15% Azelastine Hydrochloride

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First Observation December 13, 2007 Last Observation February 21, 2008

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Placebo	Placebo Nasal Spray/2 sprays per nostril once daily for 14 days
Astepro 0.15%	0.15% Azelastine Hydrochloride Nasal Spray/2 sprays per nostril once daily for 14 days

Participant Flow: Overall Study

	Placebo	Astepro 0.15%
STARTED	268 ^[1]	268 ^[1]
COMPLETED	250	249
NOT COMPLETED	18	19
Adverse Event	3	4
Lack of Efficacy	2	3
Non-Compliance	0	4
Withdrawal by Subject	1	2
Lost to Follow-up	3	2
Other	9	4

[1]	2 subjects were randomized in error

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Placebo	Placebo Nasal Spray/2 sprays per nostril once daily for 14 days
Astepro 0.15%	0.15% Azelastine Hydrochloride Nasal Spray/2 sprays per nostril once daily for 14 days

Baseline Measures

	Placebo	Astepro 0.15%	Total
Number of Participants [units: participants]	266	266	532
Age ^[1] [units: participants]
<=18 years	14	20	34
Between 18 and 65 years	241	230	471
>=65 years	11	16	27
Age ^[1] [units: years] Mean ± Standard Deviation	39.5 ± 14.41	40.9 ± 14.51	40.2 ± 14.46
Gender ^[1] [units: participants]
Female	171	175	346
Male	95	91	186
Region of Enrollment ^[1] [units: participants]
United States	266	266	532

[1]	Number of participants based on ITT population

Outcome Measures

Show All Outcome Measures

1. Primary:

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days [ Time Frame: baseline and 14 days ]

Show Outcome Measure 1

2. Secondary:

Mean Change From Baseline in Instantaneous Total Nasal Symptom Score (AM) for the Entire 14-day Study Period Compared to Placebo. [ Time Frame: basline and 14 days ]

Show Outcome Measure 2

3. Secondary:

Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (AM and PM Combined) at 14 Days [ Time Frame: baseline and 14-days ]

Show Outcome Measure 3

4. Secondary:

Change From Baseline in 12-hour Reflective Secondary Symptom Complex Score (SSCS) for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined) [ Time Frame: baseline and 14-days ]

Show Outcome Measure 4

5. Secondary:

Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) [ Time Frame: baseline and 14 Days ]

Show Outcome Measure 5

6. Secondary:

Change From Baseline on Direct Visual Nasal Exams at 14 Days [ Time Frame: baseline and 14 Days ]

Show Outcome Measure 6

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: For multicenter studies, joint publication is required to assure that the initial publication is based on all data from all sites and investigators participating in these studies agree not to present data gathered individually or by subgroup centers before the initial publication unless jointly agreed by all other investigators and the sponsor. authorship will be determined by mutual agreement.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: William Wheeler, PhD
Organization: Meda Pharmaceuticals
phone: 732-564-2393
e-mail: WWheeler@medapharma.us

No publications provided

Responsible Party:	Harry Sacks, MD Vice President, Medical and Scientific Affairs
ClinicalTrials.gov Identifier:	NCT00660829 History of Changes
Other Study ID Numbers:	MP440
Study First Received:	April 14, 2008
Results First Received:	September 30, 2009
Last Updated:	February 19, 2010
Health Authority:	United States: Food and Drug Administration